» Articles » PMID: 23902233

Development of the Performance of the Upper Limb Module for Duchenne Muscular Dystrophy

Abstract

Aim: An international Clinical Outcomes Group consisting of clinicians, scientists, patient advocacy groups, and industries identified a need for a scale to measure motor performance of the upper limb. We report the steps leading to the development of the Performance of the Upper Limb (PUL), a tool specifically designed for assessing upper limb function in ambulant and non-ambulant patients with Duchenne muscular dystrophy (DMD).

Method: The development of the PUL followed a number of steps, from the systematic review and a preliminary study exploring the suitability of the existing measures, to the application of a pilot version in a multicentric setting, with Rasch analysis of the preliminary results, leading to a revised pro forma.

Results: The PUL was specifically designed for DMD, with a conceptual framework reflecting the progression of weakness and natural history of functional decline in DMD. Modern psychometric methods were used to create a scale with robust internal reliability, validity, and hierarchical scalability; males with DMD and their families were involved iteratively throughout the process of the clinician-reported outcome assessment tool development to establish clinical meaningfulness and relevance of individual PUL items to activities of daily living.

Interpretation: The module was developed using innovative approaches and will be useful for designing clinical trials.

Citing Articles

Prospective observational study of FKRP-related limb-girdle muscular dystrophy R9: A GRASP consortium study.

Alfano L, James M, Grosfjeld Petersen K, Rudolf K, Vissing J, Augsburger R Ann Clin Transl Neurol. 2024; 12(2):332-344.

PMID: 39675022 PMC: 11822816. DOI: 10.1002/acn3.52276.


Pelvic obliquity, trunk control, and motor function: an exploratory study in a non-ambulatory Duchenne muscular dystrophy cohort.

Ugur F, Gurbuz I, Koken O, Citak Kurt A, Yilmaz O Rev Assoc Med Bras (1992). 2024; 70(12):e20241109.

PMID: 39630734 PMC: 11639577. DOI: 10.1590/1806-9282.20241109.


Characterization of patients with Duchenne muscular dystrophy across previously developed health states.

Muntoni F, Goemans N, Posner N, Signorovitch J, Johnson M, He C PLoS One. 2024; 19(10):e0307118.

PMID: 39475941 PMC: 11524485. DOI: 10.1371/journal.pone.0307118.


Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy.

Harper A, Topaloglu H, Mercuri E, Suslov V, Wu L, Ayanoglu C Sci Rep. 2024; 14(1):23488.

PMID: 39379403 PMC: 11461856. DOI: 10.1038/s41598-024-70783-y.


"If you cannot measure it, you cannot improve it". Outcome measures in Duchenne Muscular Dystrophy: current and future perspectives.

Benemei S, Gatto F, Boni L, Pane M Acta Neurol Belg. 2024; 125(1):1-12.

PMID: 39080230 PMC: 11876273. DOI: 10.1007/s13760-024-02600-2.